Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Intelligent Bio Solutions Inc.
INBS
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $1.4M
$2.24
▲ +0.45%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.08 - $24.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 87.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Non-invasive saliva-based testing technology reducing patient discomfort
- Proprietary organic thin-film transistor (OTFT) biosensor platform
- Real-time monitoring capabilities enabling immediate health insights
- Diversified diagnostic modalities across multiple disease states
Bear Case
1 risk
- Very high volatility (beta 4.2). Expect 3x market swings. Position size accordingly.
Growth
Strong growth ahead
Rising global diabetes prevalence and demand for convenient management solutions
Value
Valuation data unavailable
Momentum
Weak
-18.9% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INBS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 14, 2026
MAY 13, 2026
Reported EPS of -$1.80 vs $1.40 consensus (-228.6% surprise). Revenue of $1.1M vs $7.2M expected (-85.3%).
EPS surprise · last 4Q
0 of 2 beats
Q2 26
-228.6%
Q2 26
-228.6%
Next: Aug 14, 2026
Revenue trend · last 8Q
—
—
—
—
-12%
+16%
+27%
+48%
Q3 24
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
$823.8K
$727.8K
$872.3K
$607.5K
$728.9K
$843.9K
$1.1M
$896.8K
Margins · last 8Q
Gross
19.8%
Profit
-298.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.